APP Pharmaceuticals Announces Approval and Launch of Clonidine Hydrochloride Injection
7/11/2011 9:58:48 AM
SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths. Clonidine Hydrochloride Injection is therapeutically equivalent to the reference-listed drug Duraclon®, currently marketed by the innovator Astellas U.S. Holding, Inc. (formerly Yamanouchi U.S. Holding Inc.).
comments powered by